BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

990 related articles for article (PubMed ID: 11305846)

  • 1. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness of generic agents in psychopharmacologic treatment.
    Kumet R; Gelenberg AJ
    Essent Psychopharmacol; 2005; 6(2):104-11. PubMed ID: 15765794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the bioequivalence of generic versus branded clozapine.
    Ereshefsky L; Glazer WM
    J Clin Psychiatry; 2001; 62 Suppl 5():25-7. PubMed ID: 11305845
    [No Abstract]   [Full Text] [Related]  

  • 5. What makes a generic medication generic?
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2009 Dec; 47(12):17-20. PubMed ID: 20000278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic substitution: issues for problematic drugs.
    Henderson JD; Esham RH
    South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the bioavailability and bioequivalence of generic medications.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NerveCenter: FDA requirements for generic drug applications.
    Ann Neurol; 2010 Sep; 68(3):A11. PubMed ID: 20818779
    [No Abstract]   [Full Text] [Related]  

  • 9. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
    Bialer M; Midha KK
    Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients.
    Cutler NR
    J Clin Psychiatry; 2001; 62 Suppl 5():10-3; discussion 23-4. PubMed ID: 11305842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence studies for levothyroxine.
    Bolton S
    AAPS J; 2005 Mar; 7(1):E47-53. PubMed ID: 16146349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability and bioequivalence requirements; abbreviated applications; proposed revisions--FDA. Proposed rule.
    Fed Regist; 1998 Nov; 63(223):64222-8. PubMed ID: 10339051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In U.S., biosimilars still await FDA decision.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):435. PubMed ID: 16595775
    [No Abstract]   [Full Text] [Related]  

  • 18. Determination of bioequivalence of psychotropic drugs and concerns involving product interchange.
    Barone JA; Byerly WG
    J Clin Psychiatry; 1986 Sep; 47 Suppl():28-32. PubMed ID: 2875067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The generic drug approval process.
    Rheinstein PH
    Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 50.